RXRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Recursion Pharmaceuticals Inc (RXRX) is not a strong buy for a beginner, long-term investor at this time. While the company has shown impressive revenue growth, its financial performance is weighed down by significant net income and EPS declines. The technical indicators are neutral, and there are no strong trading signals or positive catalysts to justify immediate investment. Analysts have also lowered the price target, reflecting cautious sentiment. Given the lack of strong buy signals and the investor's preference for long-term growth, holding off on this stock for now is the most prudent choice.
The MACD is positive at 0.0832 and contracting, indicating a neutral to slightly bullish trend. RSI is at 65.68, which is in the neutral zone. Moving averages are converging, and the stock is trading near its pivot level of 3.401, with resistance at 3.772 and support at 3.031. Overall, the technical indicators suggest no clear direction.
Revenue increased significantly by 681.74% YoY in Q4 2025, showing strong top-line growth.
Net income dropped by -39.56% YoY, and EPS declined by -60.38% YoY. Gross margin also fell significantly by -132.98% YoY. Analysts have lowered the price target, and there are no recent positive news or trading trends.
In Q4 2025, revenue increased to $35.54 million, up 681.74% YoY. However, net income dropped to -$108.12 million, down -39.56% YoY, and EPS fell to -0.21, down -60.38% YoY. Gross margin also declined to 59.83, down -132.98% YoY, indicating worsening profitability.
BofA recently lowered the price target from $7 to $6 and maintained a Neutral rating, citing revised estimates and delayed product launch timelines.
